RESUMEN
INTRODUCTION: Brain metastases from epithelial ovarian cancer (EOC) are rare events. We present a rare case of single ovarian cancer metastasis to the brain treated with gamma-knife radiosurgery (GKRS). CASE OUTLINE: A 65-year-old woman with advanced EOC presented with severe neurologic symptoms. A single brain metastasis of 3.2 cm with surrounding edema in the left parietal lobe was detected by brain magnetic resonance imaging (MRI) scan during the work-up. The decision to perform GKRS was due to a surgical inaccessibility of intracranial lesion. Twelve weeks after the procedure, the MRI scan showed reduction in the diameter of brain metastasis and surrounding edema and the patient returned to good mental and motor performance.The patient survived for 22 months following treatment and died from a progressive intra-abdominal disease. Prognosis of ovarian cancer patients with brain metastases is generally poor regardless of treatment. CONCLUSION: Our case shows that GKRS as primary treatment modality for the control of ovarian cancer metastases to the brain was effective and can be considered as a treatment of choice if international selection criteria are followed.
Asunto(s)
Neoplasias Encefálicas/secundario , Estadificación de Neoplasias , Neoplasias Glandulares y Epiteliales/patología , Neoplasias Ováricas/patología , Radiocirugia/instrumentación , Anciano , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/cirugía , Carcinoma Epitelial de Ovario , Resultado Fatal , Femenino , Humanos , Imagen por Resonancia Magnética , Neoplasias Glandulares y Epiteliales/cirugía , Neoplasias Ováricas/cirugía , PronósticoRESUMEN
GOAL OF WORK: The aim of the study was to investigate the incidence of herpes simplex virus-1 (HSV-1) infection in mucositis during head and neck cancer radiotherapy. PATIENTS AND METHODS: Sixty patients with malignant head and neck tumor, eligible to receive radiotherapy, who were referred to the Dental Oncology Unit, entered the study. Sixteen patients (26.6%) received concomitant chemotherapy. Mucositis was recorded weekly. Smears taken from the ulcers of mucositis grade 2, or 3, or 4 were stained with Papanicolaou and alkaline phosphatase/antialkaline phosphatase immunocytochemical method to identify HSV-1. MAIN RESULTS: Forty-eight of all 60 patients developed ulcerative mucositis. Smear was available from 29 of 48 patients with ulcerations. HSV-1 infection was identified in 14 of 29 smears available (48.2%). Mucositis healed or was reduced after 1 week of antiviral treatment in 11 of those 14 HSV-1-positive patients; 3 patients responded to 1 g/day of valacyclovir, 7-2 g/day, and 1 patient responded to i.v. acyclovir. Ulcerations recurred after quitting antivirals. Three patients did not respond to 1 g/day of valacyclovir. No HSV-1-negative patient responded to acyclovir (P = 0.000). CONCLUSION: HSV-1 was isolated from 14 of 29 available smears taken from 48 patients with ulcerative mucositis. The incidence of HSV-1 infection during radiotherapy was estimated as being 14 of all 48 patients at risk (29.1%). Healing or reduction in the grade of mucositis after antivirals in HSV-1 positive patients, combined with the negative response to antivirals in HSV-1 negative patients, denoted that HSV-1 infection was a component of ulcerative radiation mucositis in those HSV-1-positive patients.
Asunto(s)
Anomalías Inducidas por Radiación/etiología , Neoplasias de Cabeza y Cuello/radioterapia , Herpes Simple/virología , Herpesvirus Humano 1 , Úlceras Bucales/etiología , Estomatitis/etiología , Anomalías Inducidas por Radiación/tratamiento farmacológico , Anomalías Inducidas por Radiación/virología , Aciclovir/análogos & derivados , Aciclovir/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antivirales/uso terapéutico , Candidiasis Bucal/etiología , Relación Dosis-Respuesta en la Radiación , Femenino , Herpes Simple/tratamiento farmacológico , Herpesvirus Humano 1/aislamiento & purificación , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Úlceras Bucales/tratamiento farmacológico , Úlceras Bucales/epidemiología , Radioterapia/efectos adversos , Recurrencia , Estomatitis/tratamiento farmacológico , Estomatitis/virología , Resultado del Tratamiento , Valaciclovir , Valina/análogos & derivados , Valina/uso terapéuticoRESUMEN
GOAL OF WORK: The aim of the study is to evaluate the effect of fluconazole antifungal prophylaxis on the severity of mucositis in head and neck cancer patients receiving radiotherapy. PATIENTS AND METHODS: Sixty-three patients, with malignant head and neck tumor, eligible to receive radiotherapy, entered the study. Thirty-four patients (group A) received 100 mg/day of fluconazole prophylaxis during radiotherapy and were compared with 29 patients, who received radiotherapy alone (group B). The two groups were similar in terms of patients and radiotherapy characteristics. Smear to test for Candida carriage was taken before and after radiotherapy. Oral candidiasis was diagnosed using the criteria described before. Oral mucositis was recorded according to EORTC/RTOG criteria. MAIN RESULTS: A significant reduction of severe mucositis at the end of radiotherapy (14.7 vs 44.8%, p=0.018) and of interruptions (0 vs 17.2%, p=0.017) was observed in group A. Candidiasis was prevented (0 vs 34.5%, p=0.001), with a significant reduction of Candida carriage of 40.7% (p=0.001). CONCLUSION: Fluconazole prophylaxis showed a significant beneficial impact on the severity of mucositis and on radiotherapy interruptions in this group of patients. The current study provides data on the build of a randomized controlled trial on the effect of fluconazole prophylaxis on treatment schedule and quality of life of the patients during head and neck radiotherapy.
Asunto(s)
Antifúngicos/uso terapéutico , Fluconazol/uso terapéutico , Neoplasias de Cabeza y Cuello/radioterapia , Traumatismos por Radiación/prevención & control , Estomatitis/etiología , Estomatitis/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Candidiasis Bucal/etiología , Candidiasis Bucal/prevención & control , Farmacorresistencia Fúngica , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Traumatismos por Radiación/etiología , Traumatismos por Radiación/patología , Radioterapia/efectos adversos , Índice de Severidad de la Enfermedad , Estomatitis/patología , Resultado del TratamientoRESUMEN
The present study involves non-small cell lung (NSCLC) cancer patients with brain metastases, who were treated with radiation therapy, and our aim was to determine response rate and survival. A total of 167 patients were recruited, 155 (125 male, 30 female) of whom were evaluable. Performance status was 0-2 and histology or cytology included 66 (42.58%) adenocarcinomas, 62 (40.00%) undifferentiated and 27 (17.42%) squamous cell carcinomas. The stage of disease at diagnosis was IIIA-B in 92 (59.35%) patients and IV in 63 (40.65%). All patients had whole brain irradiation (3 Gy x 5 days/week for 2 weeks to a total dose of 30 Gy), which was performed by a linear accelerator and a 6-MV photon beam. Objective response was observed in 59/155 (38.06%) patients with 17 (10.97%) complete and 42 (27.09%) partial responses, and median survival of 5 months for all patients [95% confidence interval (CI) 3.9-6.1]. Responders had statistically significant longer survival than non-responders. Although responders represented less than half of our patients with NSCLC and brain metastases, they had significantly longer survival.